Lancet[journal] 检索结果

141. ReEBOV Antigen Rapid Test kit for Ebola.

作者: Frédéric Janvier.;Emmanuel Sagui.;Vincent Foissaud.
来源: Lancet. 2015年386卷10010期2254-5页

142. ReEBOV Antigen Rapid Test kit for Ebola.

作者: Stephan Ölschläger.;Markus Heß.
来源: Lancet. 2015年386卷10010期2254页

143. ReEBOV Antigen Rapid Test kit for Ebola.

作者: Willy Urassa.;Robyn Meurant.;David Wood.
来源: Lancet. 2015年386卷10010期2253-4页

144. Treating snake bites--a call for partnership.

作者: Lembit Rägo.;Ana M Padilla Marroquin.;C Micha Nübling.;Jacqueline Sawyer.
来源: Lancet. 2015年386卷10010期2252页

145. Snake bites and antivenom shortage in Africa.

作者: Jean-Philippe Chippaux.;Achille Massougbodji.;Amadou Diouf.;Cellou M Baldé.;Leslie V Boyer.
来源: Lancet. 2015年386卷10010期2252-3页

146. Tackling preventable diseases in Yemen.

作者: Abdulhadi A Alamodi.;Abdulaziz M Eshaq.;Ahmed M Fothan.;Abdulrahman M Bakather.;Adam S Obad.
来源: Lancet. 2015年386卷10010期2251-2页

147. Health consequences of the blockade in Nepal.

作者: Jaya Lamichhane.
来源: Lancet. 2015年386卷10010期2251页

148. Ethiopia could be a model country for tuberculosis control.

作者: Talha Burki.
来源: Lancet. 2015年386卷10010期2241-2页

149. 5 years of austerity takes its toll on Greek health care.

作者: Eva Karamanoli.
来源: Lancet. 2015年386卷10010期2239-40页

150. Opening the GATE to inclusion for people with disabilities.

作者: Chapal Khasnabis.;Zafar Mirza.;Malcolm MacLachlan.
来源: Lancet. 2015年386卷10010期2229-30页

151. Nepal: man-made disaster looms.

来源: Lancet. 2015年386卷10010期2228页

152. The death of AIDS--expected or exaggerated?

来源: Lancet. 2015年386卷10010期2228页

153. Adolescent health: boys matter too.

来源: Lancet. 2015年386卷10010期2227页

154. A comparison of health expectancies over two decades in England: results of the Cognitive Function and Ageing Study I and II.

作者: Carol Jagger.;Fiona E Matthews.;Pia Wohland.;Tony Fouweather.;Blossom C M Stephan.;Louise Robinson.;Antony Arthur.;Carol Brayne.; .
来源: Lancet. 2016年387卷10020期779-86页

Whether rises in life expectancy are increases in good-quality years is of profound importance worldwide, with population ageing. We investigate how various health expectancies have changed in England between 1991 and 2011, with identical study design and methods in each decade.

155. Effects of evidence-based strategies to reduce the socioeconomic gradient of uptake in the English NHS Bowel Cancer Screening Programme (ASCEND): four cluster-randomised controlled trials.

作者: Jane Wardle.;Christian von Wagner.;Ines Kralj-Hans.;Stephen P Halloran.;Samuel G Smith.;Lesley M McGregor.;Gemma Vart.;Rosemary Howe.;Julia Snowball.;Graham Handley.;Richard F Logan.;Sandra Rainbow.;Steve Smith.;Mary C Thomas.;Nicholas Counsell.;Steve Morris.;Stephen W Duffy.;Allan Hackshaw.;Sue Moss.;Wendy Atkin.;Rosalind Raine.
来源: Lancet. 2016年387卷10020期751-9页

Uptake in the national colorectal cancer screening programme in England varies by socioeconomic status. We assessed four interventions aimed at reducing this gradient, with the intention of improving the health benefits of screening.

156. Equal access to colorectal cancer screening.

作者: Marie-Louise Essink-Bot.;Evelien Dekker.
来源: Lancet. 2016年387卷10020期724-6页

157. What can we expect of health in old age?

作者: Kenneth Rockwood.
来源: Lancet. 2016年387卷10020期730-1页

158. Ibrutinib--a new standard treatment for relapsed mantle cell lymphoma?

作者: Peter Martin.
来源: Lancet. 2016年387卷10020期728-9页

159. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.

作者: Martin Dreyling.;Wojciech Jurczak.;Mats Jerkeman.;Rodrigo Santucci Silva.;Chiara Rusconi.;Marek Trneny.;Fritz Offner.;Dolores Caballero.;Cristina Joao.;Mathias Witzens-Harig.;Georg Hess.;Isabelle Bence-Bruckler.;Seok-Goo Cho.;John Bothos.;Jenna D Goldberg.;Christopher Enny.;Shana Traina.;Sriram Balasubramanian.;Nibedita Bandyopadhyay.;Steven Sun.;Jessica Vermeulen.;Aleksandra Rizo.;Simon Rule.
来源: Lancet. 2016年387卷10020期770-8页

Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the efficacy and safety of ibrutinib versus temsirolimus in relapsed or refractory mantle-cell lymphoma.

160. New option for primary stroke prevention in sickle cell anaemia.

作者: Michael R DeBaun.;Fenella J Kirkham.
来源: Lancet. 2016年387卷10019期626-627页

结果排序

文献格式

出版时间

出版类型

出版语言